1226 related articles for article (PubMed ID: 34058265)
1. Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism.
Policard M; Jain S; Rego S; Dakshanamurthy S
Virus Res; 2021 Aug; 301():198464. PubMed ID: 34058265
[TBL] [Abstract][Full Text] [Related]
2. Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism.
Policard M; Jain S; Rego S; Dakshanamurthy S
bioRxiv; 2021 Mar; ():. PubMed ID: 33619493
[TBL] [Abstract][Full Text] [Related]
3. Differential Co-Expression Network Analysis Reveals Key Hub-High Traffic Genes as Potential Therapeutic Targets for COVID-19 Pandemic.
Hasankhani A; Bahrami A; Sheybani N; Aria B; Hemati B; Fatehi F; Ghaem Maghami Farahani H; Javanmard G; Rezaee M; Kastelic JP; Barkema HW
Front Immunol; 2021; 12():789317. PubMed ID: 34975885
[TBL] [Abstract][Full Text] [Related]
4. Single-Cell and Bulk RNASeq Profiling of COVID-19 Patients Reveal Immune and Inflammatory Mechanisms of Infection-Induced Organ Damage.
Bass A; Liu Y; Dakshanamurthy S
Viruses; 2021 Dec; 13(12):. PubMed ID: 34960687
[TBL] [Abstract][Full Text] [Related]
5. Transcriptome of nasopharyngeal samples from COVID-19 patients and a comparative analysis with other SARS-CoV-2 infection models reveal disparate host responses against SARS-CoV-2.
Islam ABMMK; Khan MA; Ahmed R; Hossain MS; Kabir SMT; Islam MS; Siddiki AMAMZ
J Transl Med; 2021 Jan; 19(1):32. PubMed ID: 33413422
[TBL] [Abstract][Full Text] [Related]
6. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 Variants, Vaccines, and Host Immunity.
Mistry P; Barmania F; Mellet J; Peta K; Strydom A; Viljoen IM; James W; Gordon S; Pepper MS
Front Immunol; 2021; 12():809244. PubMed ID: 35046961
[TBL] [Abstract][Full Text] [Related]
8. Robust Virus-Specific Adaptive Immunity in COVID-19 Patients with SARS-CoV-2 Δ382 Variant Infection.
Fong SW; Yeo NK; Chan YH; Goh YS; Amrun SN; Ang N; Rajapakse MP; Lum J; Foo S; Lee CY; Carissimo G; Chee RS; Torres-Ruesta A; Tay MZ; Chang ZW; Poh CM; Young BE; Tambyah PA; Kalimuddin S; Leo YS; Lye DC; Lee B; Biswas S; Howland SW; Renia L; Ng LFP
J Clin Immunol; 2022 Feb; 42(2):214-229. PubMed ID: 34716845
[TBL] [Abstract][Full Text] [Related]
9. Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks.
Cao M; Su X; Jiang S
Stem Cell Reports; 2021 Mar; 16(3):398-411. PubMed ID: 33691145
[TBL] [Abstract][Full Text] [Related]
10. A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance.
Anisul M; Shilts J; Schwartzentruber J; Hayhurst J; Buniello A; Shaikho Elhaj Mohammed E; Zheng J; Holmes M; Ochoa D; Carmona M; Maranville J; Gaunt TR; Emilsson V; Gudnason V; McDonagh EM; Wright GJ; Ghoussaini M; Dunham I
Elife; 2021 Aug; 10():. PubMed ID: 34402426
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
12. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
Rohilla S
Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
[TBL] [Abstract][Full Text] [Related]
13. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
[TBL] [Abstract][Full Text] [Related]
14. Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects.
Zheng J; Deng Y; Zhao Z; Mao B; Lu M; Lin Y; Huang A
Cell Mol Immunol; 2022 Feb; 19(2):150-157. PubMed ID: 34645940
[TBL] [Abstract][Full Text] [Related]
15. Systems Immunology Analysis Reveals the Contribution of Pulmonary and Extrapulmonary Tissues to the Immunopathogenesis of Severe COVID-19 Patients.
Hammoudeh SM; Hammoudeh AM; Bhamidimarri PM; Al Safar H; Mahboub B; Künstner A; Busch H; Halwani R; Hamid Q; Rahmani M; Hamoudi R
Front Immunol; 2021; 12():595150. PubMed ID: 34262555
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies.
Salimi-Jeda A; Abbassi S; Mousavizadeh A; Esghaie M; Bokharaei-Salim F; Jeddi F; Shafaati M; Abdoli A
Int Immunopharmacol; 2021 Dec; 101(Pt A):108232. PubMed ID: 34673335
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 activates lung epithelial cell proinflammatory signaling and leads to immune dysregulation in COVID-19 patients.
Chen H; Liu W; Wang Y; Liu D; Zhao L; Yu J
EBioMedicine; 2021 Aug; 70():103500. PubMed ID: 34311326
[TBL] [Abstract][Full Text] [Related]
19. Understanding the immunological aspects of SARS-CoV-2 causing COVID-19 pandemic: A therapeutic approach.
Das A; Roy S; Swarnakar S; Chatterjee N
Clin Immunol; 2021 Oct; 231():108804. PubMed ID: 34303849
[TBL] [Abstract][Full Text] [Related]
20. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
Abdurrahman L; Fang X; Zhang Y
Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
